Insulin Needs after CD3Antibody Therapy in New-Onset Type 1 Diabetes

Insulin Needs after CD3Antibody Therapy in New-Onset Type 1 Diabetes,Bart Keymeulen,Evy Vandemeulebroucke,Anette G. Ziegler,Chantal Mathieu,Leonard Ka

Insulin Needs after CD3Antibody Therapy in New-Onset Type 1 Diabetes   (Citations: 97)
BibTex | RIS | RefWorks Download
Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler, Chantal Mathieu, Leonard Kaufman, Geoff Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon, Liliane Schandene, Laurent Crenier
background Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized anti- body, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3). methods In a multicenter study, 80 patients with new-onset type 1 diabetes were randomly as- signed to receive placebo or ChAglyCD3 for six consecutive days. Patients were followed for 18 months, during which their daily insulin needs and residual beta-cell function were assessed according to glucose-clamp-induced C-peptide release before and after the administration of glucagon. results At 6, 12, and 18 months, residual beta-cell function was better maintained with ChAglyCD3 than with placebo. The insulin dose increased in the placebo group but not in the ChAglyCD3 group. This effect of ChAglyCD3 was most pronounced among patients with initial residual beta-cell function at or above the 50th percentile of the 80 patients. In this subgroup, the mean insulin dose at 18 months was 0.22 IU per kilo- gram of body weight per day with ChAglyCD3, as compared with 0.61 IU per kilogram with placebo (P<0.001). In this subgroup, 12 of 16 patients who received ChAglyCD3 (75 percent) received minimal doses of insulin (≤0.25 IU per kilogram per day) as com- pared with none of the 21 patients who received placebo. Administration of ChAglyCD3 was associated with a moderate "flu-like" syndrome and transient symptoms of Ep- stein-Barr viral mononucleosis. conclusions Short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes. abstract
Published in 2010.
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: